FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4382025360> ?p ?o ?g. }

• W4382025360 abstract "Abstract Skin toxicities are the most common immune-related adverse events (irAEs) associated with immune checkpoint inhibitor (ICI) treatment, an emerging field in dermatology. A wide spectrum of skin irAEs, including lichenoid reactions, vitiligo, bullous pemphigoid and other autoimmune skin diseases, have been reported. Psoriasiform irAEs may occur as an exacerbation of pre-existing disease or de novo and often occur later than other skin irAEs. Most cases reported to date are of chronic plaque and palmoplantar psoriasis. Generalized pustular psoriasis has been reported in fewer than 10 cases. We present a patient with mild pre-existing psoriasis who developed plaque psoriasis, evolving into severe pustular psoriasis after 4 months of pembrolizumab therapy for lung cancer. A 67-year-old man with stage 4 lung adenocarcinoma developed a widespread, itchy psoriasiform rash 3 months after starting pembrolizumab. He had a history of rheumatoid arthritis (RA) and pembrolizumab was started when he had progressed through chemotherapy. The RA was controlled on prednisolone, which was increased when methotrexate was discontinued shortly after diagnosis of lung cancer. He had a family history of psoriasis, and although he had previously been noted to have limited plaque and nail psoriasis, this had required minimal treatment. Within 2 months of starting pembrolizumab, he developed scaly, red plaques affecting more than 30% body surface area (BSA). The oncology team diagnosed a grade 3 skin toxicity and increased doses of oral steroids. Upon steroid tapering, the rash flared and was diagnosed in dermatology as consistent with exacerbation of pre-existing plaque psoriasis secondary to pembrolizumab and high-dose steroids. He partially responded to skin-directed treatment, but 2 months later following his sixth cycle of pembrolizumab, he progressed to generalized suberythrodermic pustular psoriasis. He was treated with acitretin and methotrexate. The incidence of ICI-mediated psoriasis and psoriasiform irAEs is approximately 4% of all skin toxicities. A cohort study by the European Network for Cutaneous Adverse Event to Oncologic Drugs group reported that 70% of 115 patients had no history of psoriasis. Ten per cent of psoriasiform irAEs were categorized as severe, involving more than 30% BSA. However, only eight (7%) had pustular involvement and 2% erythroderma. Treatment options include acitretin, methotrexate, apremilast and biologics. Guttate psoriasis and grade 2/3 disease were significant positive predictors for the antitumour response of ICIs. In summary, ICI-related psoriasis is an increasingly common problem with widespread use of immunotherapy. Early diagnosis and adequate management with agents that do not interfere with immunotherapy, or with the underlying malignancy, and close liaison with oncology are crucial." @default.
• W4382025360 created "2023-06-27" @default.
• W4382025360 creator A5000557436 @default.
• W4382025360 creator A5002221059 @default.
• W4382025360 creator A5024628157 @default.
• W4382025360 creator A5044662843 @default.
• W4382025360 creator A5060063665 @default.
• W4382025360 creator A5092263528 @default.
• W4382025360 date "2023-06-01" @default.
• W4382025360 modified "2023-10-16" @default.
• W4382025360 title "BI20 Generalized pustular psoriasis in a patient receiving pembrolizumab for metastatic lung adenocarcinoma" @default.
• W4382025360 doi "https://doi.org/10.1093/bjd/ljad113.188" @default.
• W4382025360 hasPublicationYear "2023" @default.
• W4382025360 type Work @default.
• W4382025360 citedByCount "1" @default.
• W4382025360 countsByYear W43820253602023 @default.
• W4382025360 crossrefType "journal-article" @default.
• W4382025360 hasAuthorship W4382025360A5000557436 @default.
• W4382025360 hasAuthorship W4382025360A5002221059 @default.
• W4382025360 hasAuthorship W4382025360A5024628157 @default.
• W4382025360 hasAuthorship W4382025360A5044662843 @default.
• W4382025360 hasAuthorship W4382025360A5060063665 @default.
• W4382025360 hasAuthorship W4382025360A5092263528 @default.
• W4382025360 hasBestOaLocation W43820253601 @default.
• W4382025360 hasConcept C121608353 @default.
• W4382025360 hasConcept C126322002 @default.
• W4382025360 hasConcept C16005928 @default.
• W4382025360 hasConcept C2776256026 @default.
• W4382025360 hasConcept C2777014857 @default.
• W4382025360 hasConcept C2777701055 @default.
• W4382025360 hasConcept C2778570526 @default.
• W4382025360 hasConcept C2780057760 @default.
• W4382025360 hasConcept C2780564577 @default.
• W4382025360 hasConcept C71924100 @default.
• W4382025360 hasConceptScore W4382025360C121608353 @default.
• W4382025360 hasConceptScore W4382025360C126322002 @default.
• W4382025360 hasConceptScore W4382025360C16005928 @default.
• W4382025360 hasConceptScore W4382025360C2776256026 @default.
• W4382025360 hasConceptScore W4382025360C2777014857 @default.
• W4382025360 hasConceptScore W4382025360C2777701055 @default.
• W4382025360 hasConceptScore W4382025360C2778570526 @default.
• W4382025360 hasConceptScore W4382025360C2780057760 @default.
• W4382025360 hasConceptScore W4382025360C2780564577 @default.
• W4382025360 hasConceptScore W4382025360C71924100 @default.
• W4382025360 hasIssue "Supplement_4" @default.
• W4382025360 hasLocation W43820253601 @default.
• W4382025360 hasOpenAccess W4382025360 @default.
• W4382025360 hasPrimaryLocation W43820253601 @default.
• W4382025360 hasRelatedWork W2062691140 @default.
• W4382025360 hasRelatedWork W2517747645 @default.
• W4382025360 hasRelatedWork W2521234799 @default.
• W4382025360 hasRelatedWork W2585407512 @default.
• W4382025360 hasRelatedWork W2891524425 @default.
• W4382025360 hasRelatedWork W2945780494 @default.
• W4382025360 hasRelatedWork W3037068108 @default.
• W4382025360 hasRelatedWork W3041652591 @default.
• W4382025360 hasRelatedWork W4200023723 @default.
• W4382025360 hasRelatedWork W4281564228 @default.
• W4382025360 hasVolume "188" @default.
• W4382025360 isParatext "false" @default.
• W4382025360 isRetracted "false" @default.
• W4382025360 workType "article" @default.